Peroxisome proliferator-activated receptor-γ-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia

Brain Research

Volumn 1093, Issue 1, 2006, Pages 208-218

  Chu, Kon ^a,b   Lee, Soon Tae ^a,b   Koo, Ja Seong ^c   Jung, Keun Hwa ^a,b,d   Kim, Eun Hee ^a   Sinn, Dong In ^a,b   Kim, Jeong Min ^a,b   Ko, Song Yi ^a   Kim, Se Jeong ^a   Song, Eun Chol ^a,b   Kim, Manho ^a,b   Roh, Jae Kyu ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Eulji General Hospital   (South Korea)

^d Korea Centers for Disease Control and Prevention   (South Korea)

Author keywords

Angiogenesis; Cerebral ischemia; eNOS; Ischemic tolerance; Peroxisome proliferator activated receptor agonist; Rosiglitazone

Indexed keywords

CASPASE 3; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FAS LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN BAX; ROSIGLITAZONE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ATROPHY; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN PROTECTION; BRAIN SIZE; COMPARATIVE STUDY; CONTROLLED STUDY; CONVALESCENCE; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; INFLAMMATORY INFILTRATE; MALE; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RAT; THERAPY EFFECT; TREATMENT RESPONSE;

ANIMALS; BLOTTING, WESTERN; BRAIN; CASPASE 3; CASPASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FAS LIGAND PROTEIN; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; ISCHEMIC ATTACK, TRANSIENT; MALE; MEMBRANE GLYCOPROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE III; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTORS;

ANIMALIA;

EID: 33745424209     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.03.114     Document Type: Article

References (51)

1. Baird T.A., Parsons M.W., Phanh T., Butcher K.S., Desmond P.M., Tress B.M., Colman P.G., Chambers B.R., and Davis S.M. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke 34 (2003) 2208-2214
2. Belayev L., Khoutorova L., Deisher T.A., Belayev A., Busto R., Zhang Y., Zhao W., and Ginsberg M.D. Neuroprotective effect of SolCD39, a novel platelet aggregation inhibitor, on transient middle cerebral artery occlusion in rats. Stroke 34 (2003) 758-763
3. Blanco M., Moro M.A., Davalos A., Leira R., Castellanos M., Serena J., Vivancos J., Rodriguez-Yanez M., Lizasoain I., and Castillo J. Increased plasma levels of 15-deoxyDelta prostaglandin J2 are associated with good outcome in acute atherothrombotic ischemic stroke. Stroke 36 (2005) 1189-1194
4. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., and Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 82 (2002) 615-624
5. Bulotta S., Barsacchi R., Rotiroti D., Borgese N., and Clementi E. Activation of the endothelial nitric-oxide synthase by tumor necrosis factor-alpha. A novel feedback mechanism regulating cell death. J. Biol. Chem. 276 (2001) 6529-6536
6. Camacho I.E., Serneels L., Spittaels K., Merchiers P., Dominguez D., and De Strooper B. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J. Neurosci. 24 (2004) 10908-10917
7. Chen J., Zhang Z.G., Li Y., Wang L., Xu Y.X., Gautam S.C., Lu M., Zhu Z., and Chopp M. Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ. Res. 92 (2003) 692-699
8. Chu K., Jeong S.W., Jung K.H., Han S.Y., Lee S.T., Kim M., and Roh J.K. Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death. J. Cereb. Blood Flow Metab. 24 (2004) 926-933
9. Chu K., Kim M., Park K.I., Jeong S.W., Park H.K., Jung K.H., Lee S.T., Kang L., Lee K., Park D.K., Kim S.U., and Roh J.K. Human neural stem cells improve sensorimotor deficits in the adult rat brain with experimental focal ischemia. Brain Res. 1016 (2004) 145-153
10. Collino M., Aragno M., Mastrocola R., Gallicchio M., Rosa A.C., Dianzani C., Danni O., Thiemermann C., and Fantozzi R. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur. J. Pharmacol. 530 (2006) 70-80
11. Dimmeler S., Hermann C., Galle J., and Zeiher A.M. Upregulation of superoxide dismutase and nitric oxide synthase mediates the apoptosis-suppressive effects of shear stress on endothelial cells. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 656-664
12. Duda D.G., Fukumura D., and Jain R.K. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol. Med. 10 (2004) 143-145
13. Endres M. Statins and stroke. J. Cereb. Blood Flow Metab. 25 (2005) 1093-1110
14. Endres M., Laufs U., Liao J.K., and Moskowitz M.A. Targeting eNOS for stroke protection. Trends Neurosci. 27 (2004) 283-289
15. Friedlander R.M. Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med. 348 (2003) 1365-1375
16. Furuke K., Burd P.R., Horvath-Arcidiacono J.A., Hori K., Mostowski H., and Bloom E.T. Human NK cells express endothelial nitric oxide synthase, and nitric oxide protects them from activation-induced cell death by regulating expression of TNF-alpha. J. Immunol. 163 (1999) 1473-1480
17. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
18. Hashiguchi A., Yano S., Morioka M., Hamada J., Ushio Y., Takeuchi Y., and Fukunaga K. Up-regulation of endothelial nitric oxide synthase via phosphatidylinositol 3-kinase pathway contributes to ischemic tolerance in the CA1 subfield of gerbil hippocampus. J. Cereb. Blood Flow Metab. 24 (2004) 271-279
19. Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci. 20 (1997) 132-139
20. Jeong S.W., Chu K., Jung K.H., Kim S.U., Kim M., and Roh J.K. Human neural stem cell transplantation promotes functional recovery in rats with experimental intracerebral hemorrhage. Stroke 34 (2003) 2258-2263
21. Jung K.H., Chu K., Jeong S.W., Han S.Y., Lee S.T., Kim J.Y., Kim M., and Roh J.K. HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke 35 (2004) 1744-1749
22. Kiaei M., Kipiani K., Chen J., Calingasan N.Y., and Beal M.F. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 191 (2005) 331-336
23. Lee S.R., and Lo E.H. Interactions between p38 mitogen-activated protein kinase and caspase-3 in cerebral endothelial cell death after hypoxia-reoxygenation. Stroke 34 (2003) 2704-2709
24. Lee S.H., Kim M., Yoon B.W., Kim Y.J., Ma S.J., Roh J.K., Lee J.S., and Seo J.S. Targeted hsp70.1 disruption increases infarction volume after focal cerebral ischemia in mice. Stroke 32 (2001) 2905-2912
25. Lee S.H., Kim M., Kim Y.J., Kim Y.A., Chi J.G., Roh J.K., and Yoon B.W. Ischemic intensity influences the distribution of delayed infarction and apoptotic cell death following transient focal cerebral ischemia in rats. Brain Res. 956 (2002) 14-23
26. Lee S.T., Chu K., Jung K.H., Ko S.Y., Kim E.H., Sinn D.I., Lee Y.S., Lo E.H., Kim M., and Roh J.K. Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia. Brain Res. 1058 (2005) 120-128
27. Lehrke M., and Lazar M.A. The many faces of PPARgamma. Cell 123 (2005) 993-999
28. Lin T.N., Cheung W.M., Wu J.S., Chen J.J., Lin H., Chen J.J., Liou J.Y., Shyue S.K., and Wu K.K. 15d-Prostaglandin J2 protects brain from ischemia-reperfusion injury. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 481-487
29. Liu H.R., Tao L., Gao E., Lopez B.L., Christopher T.A., Willette R.N., Ohlstein E.H., Yue T.L., and Ma X.L. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc. Res. 62 (2004) 135-144
30. Margeli A., Kouraklis G., and Theocharis S. Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis. Angiogenesis 6 (2003) 165-169
31. Marx N., Froehlich J., Siam L., Ittner J., Wierse G., Schmidt A., Scharnagl H., Hombach V., and Koenig W. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 283-288
32. Matsushita K., Meng W., Wang X., Asahi M., Asahi K., Moskowitz M.A., and Lo E.H. Evidence for apoptosis after intercerebral hemorrhage in rat striatum. J. Cereb. Blood Flow Metab. 20 (2000) 396-404
33. Panigrahy D., Singer S., Shen L.Q., Butterfield C.E., Freedman D.A., Chen E.J., Moses M.A., Kilroy S., Duensing S., Fletcher C., Fletcher J.A., Hlatky L., Hahnfeldt P., Folkman J., and Kaipainen A. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest. 110 (2002) 923-932
34. Pereira M.P., Hurtado O., Cardenas A., Alonso-Escolano D., Bosca L., Vivancos J., Nombela F., Leza J.C., Lorenzo P., Lizasoain I., and Moro M.A. The nonthiazolidinedione PPARgamma agonist L-796,449 is neuroprotective in experimental stroke. J. Neuropathol. Exp. Neurol. 64 (2005) 797-805
35. Pereira M.P., Hurtado O., Cardenas A., Bosca L., Castillo J., Davalos A., Vivancos J., Serena J., Lorenzo P., Lizasoain I., and Moro M.A. Rosiglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2) cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J. Cereb. Blood Flow Metab. 26 (2006) 218-229
36. Pistrosch F., Herbrig K., Oelschlaegel U., Richter S., Passauer J., Fischer S., and Gross P. PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 183 (2005) 163-167
37. Sakamoto J., Kimura H., Moriyama S., Odaka H., Momose Y., Sugiyama Y., and Sawada H. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem. Biophys. Res. Commun. 278 (2000) 704-711
38. Sarayba M.A., Li L., Tungsiripat T., Liu N.H., Sweet P.M., Patel A.J., Osann K.E., Chittiboyina A., Benson S.C., Pershadsingh H.A., and Chuck R.S. Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand. Exp. Eye Res. 80 (2005) 435-442
39. Shimazu T., Inoue I., Araki N., Asano Y., Sawada M., Furuya D., Nagoya H., and Greenberg J.H. A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 36 (2005) 353-359
40. Sidhu J.S., Cowan D., and Kaski J.C. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am. J. Cardiol. 94 (2004) 151-156
41. Sulejczak D., Czarkowska-Bauch J., Macias M., and Skup M. Bcl-2 and Bax proteins are increased in neocortical but not in thalamic apoptosis following devascularizing lesion of the cerebral cortex in the rat: an immunohistochemical study. Brain Res. 1006 (2004) 133-149
42. Sundararajan S., Gamboa J.L., Victor N.A., Wanderi E.W., Lust W.D., and Landreth G.E. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130 (2005) 685-696
43. Uryu S., Harada J., Hisamoto M., and Oda T. Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons. Brain Res. 924 (2002) 229-236
44. Wayman N.S., Hattori Y., McDonald M.C., Mota-Filipe H., Cuzzocrea S., Pisano B., Chatterjee P.K., and Thiemermann C. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J. 16 (2002) 1027-1040
45. Yamakawa K., Hosoi M., Koyama H., Tanaka S., Fukumoto S., Morii H., and Nishizawa Y. Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 271 (2000) 571-574
46. Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med. 351 (2004) 1106-1118
47. Yue T.L., Chen J., Bao W., Narayanan P.K., Bril A., Jiang W., Lysko P.G., Gu J.L., Boyce R., Zimmerman D.M., Hart T.K., Buckingham R.E., and Ohlstein E.H. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 104 (2001) 2588-2594
48. Zhang Z.G., Zhang L., Jiang Q., Zhang R., Davies K., Powers C., Bruggen N., and Chopp M. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J. Clin. Invest. 106 (2000) 829-838
49. Zhang Z.G., Zhang L., Jiang Q., and Chopp M. Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse. Circ. Res. 90 (2002) 284-288
50. Zhao Y., Patzer A., Gohlke P., Herdegen T., and Culman J. The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur. J. Neurosci. 22 (2005) 278-282
51. Zhao X., Zhang Y., Strong R., Grotta J.C., and Aronowski J. 15d-Prostaglandin J(2) activates peroxisome proliferator-activated receptor-gamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats. J. Cereb. Blood Flow Metab. (2005) doi:10.1038/sj.jcbfm.9600233